Recent analysis suggests that Cardano may be approaching a significant stage in its market cycle. After months of continuous decline, the asset is showing earlyRecent analysis suggests that Cardano may be approaching a significant stage in its market cycle. After months of continuous decline, the asset is showing early

Top Analyst: Cardano (ADA) is Building Foundation for Major Rally

2026/03/07 09:00
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

Recent analysis suggests that Cardano may be approaching a significant stage in its market cycle. After months of continuous decline, the asset is showing early signs of stabilization. Analysts now indicate that ADA could be forming a long-term market bottom, which may provide a base for a future upward phase.

Even with ongoing macroeconomic challenges impacting the broader cryptocurrency market, Cardano has remained relatively steady. In situations like this, many assets often experience sharper declines and hit new yearly lows. ADA, however, has largely held its key support level. This suggests that long-term holders are choosing to stay invested rather than selling off their positions.

Stabilization After Prolonged Decline

Market analyst Arman Shaban recently reviewed Cardano’s price action and observed early signs of stabilization following a lengthy downturn. ADA experienced a six-month correction that significantly reduced its market value, falling from roughly $0.95 in September to a low of $0.22 on February 6.

As the asset approached this historically important support region, buying interest increased. The heightened demand allowed ADA to rebound toward $0.31, showing that investors were willing to accumulate near the lower price range. Despite this recovery, the market has not yet transitioned into a sustained upward trend. Following the rebound, momentum slowed, and the asset settled near $0.27, indicating a period of consolidation.

The current price behavior signals that the digital asset is approaching a longer accumulation phase. Prices tend to stabilize during such phases as market participants gradually rebuild positions and accumulate tokens, anticipating a future trend change.

The support zone near $0.22 could represent a durable bottom if it continues to hold. Sustained activity at this level would demonstrate that market participants are defending the price floor and preventing further declines. Continued consolidation could allow buying pressure to strengthen, setting the stage for a more pronounced directional move.

Outlook for the Next Bullish Cycle

If accumulation persists, Cardano could enter a new expansion phase within nine to fifteen months, aligning with late 2026 and early 2027. Analysts estimate potential gains ranging from 60% to 200%, which would place ADA between approximately $0.43 and $0.81 from the current $0.27 price.

Maintaining support between $0.24 and $0.26 is crucial. Large investors sustaining buying activity may help preserve this range, as recent data from Coinglass shows that exchange outflows have recently exceeded inflows. This trend is often associated with gradual accumulation by market participants.

Disclaimer: This content is meant to inform and should not be considered financial advice. The views expressed in this article may include the author’s personal opinions and do not represent Times Tabloid’s opinion. Readers are urged to do in-depth research before making any investment decisions. Any action taken by the reader is strictly at their own risk. Times Tabloid is not responsible for any financial losses.


Follow us on Twitter, Facebook, Telegram, and Google News

The post Top Analyst: Cardano (ADA) is Building Foundation for Major Rally appeared first on Times Tabloid.

Market Opportunity
Cardano Logo
Cardano Price(ADA)
$0.2584
$0.2584$0.2584
+0.58%
USD
Cardano (ADA) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09